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Background: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransfer-
ase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of
response to the alkylating drug temozolomide in glioblastoma. Preclinical evidences and some case reports showed
temozolomide activity in CRC with MGMT silencing, but the available data from clinical trials are inconsistent.
Methods: This was a multicentre, phase 2 trial, planned according to a two-stage Simon’s optimal design to investigate activity
and safety of temozolomide in refractory CRC harbouring MGMT promoter methylation. The primary end point was overall
response rate (ORR). Patients who failed two or more prior treatments received temozolomide at a dose of 150–200 mg m 2 per
day on days 1–5 every 28 days.
Results: From July 2012 to June 2016, 225 patients were screened, 80 showed MGMT promoter methylation and 41 were enrolled.
Overall response rate was 10% and disease control rate was 32%. Median progression-free survival and overall survival were 1.9
and 5.1 months, respectively.
Conclusions: Temozolomide showed a modest activity in this heavily pretreated population and the study did not meet its primary
end point. The role of temozolomide in CRC remains still controversial and further research is warranted.
Worldwide, colorectal cancer (CRC) is the third most commonly
diagnosed malignancy and one of the leading causes of cancer-
related deaths, with an estimated 1.4 million cases and 693 900
deaths occurring in 2012 (Torre et al, 2015). Around 25% of
patients present with metastatic disease at diagnosis and at least
50% of those with early disease eventually develop metastases (Van
Cutsem et al, 2010). Historically, for patients with unresectable
metastatic CRC (mCRC) the only available systemic treatment
was chemotherapy, including fluoropyrimidines, oxaliplatin and
irinotecan, with a median overall survival (mOS) of B20 months
(Tournigand et al, 2004). Over the past decade, the introduction of
anti-EGFR antibodies (cetuximab and panitumumab) for patients
with RAS wild-type (WT) tumours (Douillard et al, 2014; Van
Cutsem et al, 2015) and antiangiogenic agents (bevacizumab,
aflibercept and ramucirumab) has significantly improved the
outcome (Slatz et al, 2008; Van Cutsem et al, 2012; Tabernero
et al, 2015), extending mOS to almost 30 months (Cremolini
et al, 2015). More recently, the multikinase inhibitor regorafenib
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(Grothey et al, 2013) and the novel oral fluoropyrimidine TAS-102
(Mayer et al, 2015) have demonstrated efficacy in refractory
patients.
Despite such advances, prognosis of patients failing standard
therapies remains poor. However, many refractory patients still
maintain a good performance status (PS) and are potentially
suitable for further active treatment. Therefore, the development of
novel approaches for pretreated mCRC patients represents an
unmet clinical need.
Temozolomide (TMZ) is an oral alkylating agent with a broad
spectrum of antitumour activity. It is indicated for the treatment of
patients with glioblastoma (Stupp et al, 2005, 2009), and widely
used in patients with refractory metastatic melanoma (Middleton
et al, 2000; Patel et al, 2011) and advanced pancreatic neuroendo-
crine tumours (Chan et al, 2012). Its antitumour activity relies on
methylation of DNA at the O6 position of guanine, which leads to
DNA double-strand breaks and subsequent DNA replication
inhibition and apoptosis (Newlands et al, 1997). The predominant
mechanism of resistance to TMZ is the expression of O6-methyl-
guanine-DNA-methyltransferase (MGMT), a DNA repair enzyme
that removes the O6-methyl-guanine DNA adducts in a one-step
suicide reaction (Pegg, 1990; van Nifterik et al, 2010). O6-methyl-
guanine-DNA-methyltransferase levels are regulated through an
epigenetic mechanism (Heigi et al, 2005). Indeed, methylation of
the CpG dinucleotides in the promoter region leads to a
transcriptional silencing, thus causing a failure to repair the
TMZ-induced DNA damage (Esteller and Herman, 2004). Both
MGMT methylation and the absence of MGMT protein have been
associated with in vitro sensitivity to TMZ in different human
tumour cell lines. Moreover, MGMT methylation has been
identified as a prognostic factor and a predictor of response to
TMZ in glioblastoma (Hegi et al, 2005; Dunn et al, 2009).
O6-methyl-guanine-DNA-methyltransferase methylation repre-
sents a quite frequent as well as relevant event in colorectal
cancerogenesis. About 27–40% of mCRC present a low expression
of MGMT protein due to gene promoter methylation (Esteller and
Herman, 2004), with higher prevalence among CRC with KRAS
mutation (Esteller et al, 2000). In fact, in a series of 244 CRC,
MGMT methylation was found in 71% of tumours with KRAS
G4A mutations, in 32% of those with non-G4A KRAS mutations
and in 35% of WT KRAS tumours. Temozolomide showed in vitro
activity against a large variety of human tumour cell lines,
including colorectal cancer (Raymond et al, 1997). In 2011,
Shacham-Shmueli et al (2011) reported two cases of impressive
clinical response to TMZ in patients with MGMT loss of
expression. This evidence provided the rationale for investigating
TMZ in mCRC. Four mono-institutional, phase 2 trials have been
published so far with different results (Hochhauser et al, 2013;
Pietrantonio et al, 2014, 2016; Amatu et al, 2016). Here, we report
the results of a multicentre phase 2 trial assessing activity and
safety of TMZ in refractory patients with mCRC.
PATIENTS AND METHODS
Study population. Patients with histologically confirmed mCRC
harbouring MGMT promoter methylation were eligible for
inclusion if they met all of the following criteria: age X18 years;
Eastern Cooperative Oncology Group (ECOG) PS p2; life
expectancy of at least 3 months; at least one measurable lesion as
defined by Response Evaluation Criteria in Solid Tumours
(RECIST) v.1.1; failure of at least two previous chemotherapy
regimens (including fluoropyrimidines, irinotecan, oxaliplatin,
bevacizumab and, if RAS WT, an anti-EGFR antibody); radi-
ological progressive disease (PD) during or within 6 months from
the end of the previous treatment or unacceptable toxicity to the
previous treatment; adequate hepatic, renal and bone marrow
function (defined as white blood cell count X3 109/l with
absolute neutrophil count (ANC) X1.5 109/l, platelet count
X100 109/l and haemoglobin 49 g dl 1; total serum bilirubin
o1.5 times upper limit of normal (ULN), unless documented
Gilbert’s syndrome; ALTp2.5ULN or p5ULN in patients
with liver metastases; serum creatinine p1.5ULN or calculated
creatinine clearance X50 ml min 1 according to Crockcroft and
Gault; INR and aPTT p1.5ULN, unless on therapeutic
anticoagulation). Patients were ineligible if they met any of the
following exclusion criteria: history of any other severe or
uncontrolled disease; pregnancy or lactation; existing acute effects
of prior treatment; history of any other malignancy within the
previous 5 years, except for patients appropriately treated for skin
carcinoma (other than melanoma) or in situ cervical carcinoma, or
those treated with curative intent for any other cancer with no
evidence of disease for at least 5 years. The presence of MGMT
promoter methylation was assessed by methylation-specific poly-
merase chain reaction (MS-PCR), the evaluation was performed
centrally at the Institute of Pathological Anatomy of Catholic
University of the Sacred Heart. RAS and BRAF mutational genetic
analyses and mismatch repair system (MMR) status evaluation by
immunohistochemistry (IHC) were also performed. The trial was
approved by the Ethics Committee of Catholic University of the
Sacred Heart Rome and by the Institutional Review Board of each
participating centre. All patients provided written informed
consent before study entry and any protocol-specific procedure.
Study design, treatment and evaluations. This was a multicentre,
single-arm, phase 2 trial (EudraCT number: 2012-002766-13),
evaluating activity and safety of TMZ in patients with MGMT-
methylated mCRC who have failed all standard therapeutic
options.
Enrolled patients received TMZ (TEVA) orally under fasting
conditions once a day for five consecutive days every 28 days. At
each cycle, treatment was administered if ANC and platelet count
were X1.5 109/l and X100 109/l, respectively. Temozolomide
was administered at a dose of 150 mg m 2 per day for the first
cycle (level 0). If no grade 3–4 neutropenia, thrombocytopenia and
non-haematological adverse events (AEs) (except from nausea and
vomiting) occurred, the dose was increased to 200 mg m 2 per day
starting from the next cycle (level 1). In case of grade 3 or 4 toxicity
with the exception of nausea and vomiting, two dose reductions
were allowed up to 100 mg m 2 per day (level  1). If further
toxicity occurred, patients were discontinued from treatment.
Treatment was continued until occurrence of PD, unacceptable
toxicity, death or withdrawal of consent.
Pre-treatment evaluation were performed within 28 days before
starting treatment and consisted of: collection of tumour tissue
samples (blocks or slides from primary tumours or metastases) and
assessment of MGMT methylation status by MS-PCR, RAS and
BRAF mutational status and MMR expression status, medical
history, ECOG PS, physical examination, routine haematology,
biochemistry and urine analyses, electrocardiogram and contrast-
enhanced computed tomography (CT) scans or magnetic reso-
nance imaging of the chest and abdomen. On day 1 of each cycle,
treatment compliance, concomitant medications, symptoms,
physical examination, vital signs, PS and all AEs, graded according
to the National Cancer Institute Common Toxicity Criteria for
Adverse Events (NCI-CTCAE) v.4.03, were recorded. Complete
blood count and serum chemistry were obtained every month
before each cycle. Radiographic assessment of tumour response
was carried out every 8 weeks according to RECIST v.1.1
(Eisenhauer et al, 2009) until PD or consent withdrawal for any
reason.
Study end points and statistical analysis. The primary end point
was overall response rate (ORR), defined as the proportion of
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patients that achieved a confirmed complete response (CR) or a
partial response (PR) as best response. Secondary end points were:
disease control rate (DCR), defined as the proportion of patients
that achieved CR, PR or stable disease (SD), duration of response
(DoR), defined as the time from first documented response to the
date of PD or death due to any cause, whichever occurred first;
progression-free survival (PFS), defined as the time from the start
of the treatment to the date of the first documented PD or death
due to any cause, whichever occurred first; overall survival (OS),
defined as the time from the start of the treatment to the date of
death due to any cause, or censored at the date of last follow-up for
alive patients; safety profile. Preplanned exploratory analyses
evaluated the correlation between ORR and RAS and BRAF
mutational status. All assessments were conducted on the intent-
to-treat population (ITT). The Kaplan–Meier method was used to
estimate DoR, OS and PFS. Median values are presented with 95%
confidence interval (CI). The correlation between ORR and
mutational status was assessed by two-tailed Fisher’s exact test.
Adverse events are presented according to NCI-CTCAE v.4.03.
This study was planned according to a two-stage Simon’s
optimal design (Simon, 1989; Jung et al, 2008). The null hypothesis
that the true response rate is r5% (p0) was tested against a one-
sided alternative that the response rate is Z20% (p1). According to
this design, in the first stage, 21 patients (n1) were accrued: if 1 or
fewer responses (r1) were observed in this cohort of patients, the
study would be stopped early for futility; otherwise, 20 additional
patients would be accrued for a total of 41 patients (n). The null
hypothesis would be rejected if more than four responses (r2) were
observed in 41 patients (n). Thus, if four or fewer responses would
be observed by the end of stage 2, then no further investigation
would be warranted. This design yields a type I error rate of 5%
and power of 90% when the true response rate is 20%.
Data were analysed using IBM SPSS Statistics version 22
software (IBM, Armonk, NY, USA).
Assessment of MGMT gene promoter methylation with MS-
PCR. After DNA modification with Methylamp DNA Modifica-
tion Kit (Epigentek, Farmingdale, NY, USA), MS-PCR for MGMT
were determined as described previously (Martini et al, 2008).
Briefly, bisulphite-modified DNA (100–200 ng) was amplified in a
mixture containing 1PCR buffer (20 mM Tris (pH 8.3), 50 mM
KCl, 1.5 mM MgCl2), deoxynucleotide triphosphates (0.2 mM
each), primers (20 pM each) and 0.75 U GoTaq Hot Start
polymerase (Promega, Madison, WI, USA) in a final volume of
25 ml. Polymerase chain reaction conditions were: an initial
denaturation of 95 1C for 8 min, followed by 35 cycles of 95 1C
for 60 s, 60 1C for 60 s and 72 1C for 60 s. Polymerase chain
reaction products were electrophoresed in a 2.5% agarose gel,
stained with ethidium bromide and visualised under ultraviolet
illumination. Methylation-specific-PCR analysis was performed in
duplicate for all samples. Normal lymphocyte DNA supermethy-
lated with SssI methyltransferase (New England Biolabs, Beverly,
MA, USA) and treated with bisulphite was used as the
unmethylated and methylated control, water as a negative control
and untreated DNA as an internal PCR control. We also carried
out MS-PCR on granulocyte DNA obtained from 10 healthy
individuals, as the control group.
Assessment of RAS and BRAF mutational status. DNA was
extracted from three 10mm slides from paraffin-embedded tissues
using QIAamp DNA Mini Kit (Qiagen, Milan, Italy), following the
manufacturer’s protocol. KRAS and NRAS gene (2, 3 and 4 exons)
and BRAF gene (11 and 15 exons) were amplified using the same
primers and PCR conditions described previously (Basso et al,
2013). Briefly, DNA (100–200 ng) was amplified in a mixture
containing 1PCR buffer (20 mM Tris, pH 8.3, 50 mM KCl,
1.5 mM MgCl2), deoxyribonucleotide triphosphates (200 mM each),
primers (20 pM each) and 0.5 U GoTaq (Promega, Milan, Italy) in
a final volume of 25ml. After visualisation onto agarose gel, stained
with ethidium bromide and visualised under UV light, PCR
products were treated with ExoSAP-IT (GE Healthcare, Milan,
Italy) following the manufacturer’s protocol, amplified with the
BigDye Terminator Cycle-Sequencing Kit (version 3.1; Applied
Biosystems, Milan, Italy) using forward and reverse primers, and
sequenced with an ABI PRISM 3100-Avant Genetic Analyser
(Applied Biosystems). Water was used as a negative control. The
sensitivity of this method is 15% in our laboratory.
Assessment of MMR expression status. Mismatch repair system
analysis was performed on formalin-fixed paraffin-embedded
(FFPE) tissue with antibodies against proteins MLH1, MSH2,
MSH6 and PMS2. Briefly, FFPE sections (4mm thick) were
mounted on positive charged glass slides. For antigen retrieval,
deparaffinised and rehydrated sections were treated with citric acid
buffer (pH 6.0), two cycles of 3 min each at 500 W, followed by
inhibition of endogenous peroxidase with 3% H2O2 for 5 min.
Then, the sections were incubated for 1 h at room temperature with
mouse monoclonal anti-MLH-1, anti-MSH2 and anti-MSH6
(clone M1; clone G219-1129; clone 44; Roche, Monza, Italy) and
mouse monoclonal anti-human PMS2 (clone 2G5; Novus Biolo-
gicals, Milan, Italy). The primary antibodies were visualised using
the avidin–biotin–peroxidase complex. 3,30-Diaminobenzidine was
used as the enzyme substrate to observe the specific antibody
localisation and Mayer haematoxylin was used as a nuclear
counterstain. Samples were stained more than once, and the results
were highly reproducible. Staining patterns of MMR proteins were
evaluated using normal epithelial, stromal or inflammatory cells, or
centres of lymphoid follicles as internal controls. Stained slides
were scored as positive when showing nuclear staining in at least
some tumour cells (40%).
RESULTS
Patients characteristics. Between July 2012 and June 2016, a total
of 225 patients were screened. Archival tissue samples collected
from each patient were assessed for MGMT promoter methylation:
80 samples (35%) resulted positive, whereas 134 were negative and
11 did not provide adequate quality/quantity DNA to perform the
evaluation. Among the 80 patients with MGMT promoter
methylation, 41 met all the inclusion criteria, were enrolled in
the study and received study treatment (ITT population)
(Figure 1). The remaining MGMT methylated patients resul-
ted ineligible due to: hepatic impairment (51%), worsening of
clinical condition with increase of the ECOG PS43 and reduction
of life expectancy to o3 months (41%) and absence of adequate
bone marrow function due to persistence of AEs of previous
treatments (8%).
Baseline patient and disease characteristics are summarised in
Table 1. Twenty-four patients (58.5%) were female and 17 (41.5%)
male. Median age was 66 years (range 47–81). Eastern Cooperative
Oncology Group PS was 0 for 12 (29%) patients, 1 for 23 (56%)
patients and 2 for 6 (15%) patients. Primary tumour location was
rectum in 6 (15%), left colon in 27 (67.5%) and right colon in 7
(17.5%) patients. The median number of metastatic sites was 3. Six
(15%) patients had only one site involved and 14 (34%) had more
than three metastatic sites. The median number of previous
treatment lines was 3. Ten (24%) patients received more than three
lines and 3 (7%) were previously treated with regorafenib. Twenty-
three (63%) tumours were RAS mutant (MT), 2 (5%) were BRAF
MT and 13 (32%) were RAS/BRAF WT. Only one tumour (2.5%)
presented a deficient MMR, because of the lack of MLH1
expression.
Outcome. A total of 109 cycles were administered and patients
received a median of three cycles (range, 1–8). Temozolomide
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activity was evaluated in the ITT population and is summarised in
Table 2. Overall response rate was 10% with no CR and 4 (10%)
PR. Stable disease was achieved in 9 (22%) patients, accounting for
a DCR of 32%. Twenty-eight (68%) patients experienced PD as
best response (Figure 2). Thus, the primary end point of the study
was not met, not reaching the prespecified level for promising
activity. The DoR was 3.05 months (range, 2–6).
At a median follow-up time of 9 months, all patients
experienced PD and 36 (88%) patients died due to CRC.
Kaplan–Meier curves for PFS and OS are reported in Figure 3a
and b respectively. The median PFS was 1.9 months (95% CI: 1.6–
2.35) (Figure 3a) and the median OS (Figure 3b) was 5.1 months
(95% CI: 3.9–6.2). The median PFS was significantly higher for
patients achieving PR or SD as compared with patients who
experienced PD (4.7 vs 1.7 months; Po0.001). No significant
difference was observed between patients achieving PR or SD and
those with PD in terms of median OS (9.8 vs 6.4 months;
P¼ 0.245).
All patients who had a PR were RAS MT (three KRAS MT and
one NRAS MT). Of the nine patients who presented SD as best
response, six had a RAS MT tumour (five KRAS and one NRAS)
and three a RAS/BRAF WT tumour. Among the 28 patients who
experienced PD, 16 tumours were RAS MT (15 KRAS and 1
NRAS), 2 BRAF MT and 10 RAS/BRAF WT. Therefore, with regard
to the exploratory analysis, no significant correlation between RAS/
BRAF mutational status and RR (w2 test P¼ 0.49) or survival (PFS
P¼ 0.967; OS P¼ 0.912) was observed.
The only patient with MMR-deficient tumour achieved PD as
best response; the PFS and OS reached by this patient were 1.7 and
29.7 months, respectively.
Overall, 20 patients (49%) received poststudy therapy. Chemother-
apy rechallenge was administered in 10 (24%) patients, regorafenib in
6 (14.6%), capecitabine monotherapy in 4 (10%), mitomycin C in 2
(5%) and hepatic intra-arterial injection of irinotecan-eluting bead
(DEBIRI) plus systemic capecitabine in 2 (5%).
Safety. All patients received at least one cycle of treatment
and formed the safety population. Overall, 109 cycles were
administered. Treatment-related AEs are summarised in Table 3.
Any-grade AEs were reported in 31 patients (75.6%). The most
frequent haematological AE was platelet count decreased, reported
in 16 patients (39%); 13 cases of anaemia (31.7%) and 3 cases
(7.3%) of ANC decreased occurred. Two patients received blood
transfusion, whereas colony-stimulating factors were never
required. Regarding non-haematological AEs, nausea was observed
in 23 (56.1%) patients, vomiting in 15 (36.5%), constipation in 10
(24.4%), liver enzyme increased in 22 (53.6%) and fatigue in 4
(9.7%). Most AEs were grade 1 or 2 (84%). Grade 4 AEs occurred
in 6 (14.6%) patients. Overall, dose reduction was required in 11
(27%). All patients discontinued study treatment; the primary
reason for discontinuation was PD (35 patients; 85%), whereas 4
(10%) patients discontinued due to AE and 2 (5%) patients
withdrawn the consent. No serious AEs nor toxic deaths were
recorded.
DISCUSSION
Nowadays, research is actively committed in the identification of
treatment options for refractory mCRC after failure of standard
therapy. The unresolved issue is the absence of effective drugs that
could be offered to patients progressing after all approved
treatment but still in adequate clinical conditions to face further
therapy. Given the known role of MGMT promoter methylation
status as predictive biomarker of response to TMZ in glioblastoma
(Esteller and Herman, 2004; Heigi et al, 2005; van Nifterik et al,
2010), the high frequency of this epigenetic alteration in CRC
cancerogenesis (Dunn et al, 2009) and the preliminary evidence
(both from in vitro studies and clinical reports) of TMZ activity in
MGMT-methylated mCRC (Raymond et al, 1997; Shacham-
Shmueli et al, 2011, Inno et al, 2014), we hypothesised that TMZ
might represent a treatment option in pretreated mCRC selected
according to MGMT promoter methylation status. Thus, we
conducted this phase 2 study to assess the activity and safety of
TMZ in refractory mCRC harbouring MGMT promoter
methylation.
In the present study, TMZ showed some activity, with an ORR
of 10%. However, the primary end point of the study was not met
since the prespecified threshold for activity was not reached. In
fact, we observed 4 PR among 41 patients, while at least five
responses should have been observed according to the study






Assessed for eligibility (n=225)
Excluded (n=184)
Not adequate tissue samples (n=11)
Not methylated MGMT promoter (n=134)
Not meeting other inclusion criteria (n=39)
Non-randomised (n=41)
Allocated to intervention (n=41)
Received allocated intervention (n=41)
Completed intervention without dose reduction (n=24)
Completed intervention with dose reduction due to AE (n=11)
Discontinued intervention due to AE (n=4)
Discontinued intervention due to consent withdrawal (n=2)
Analysed (n=41)
Figure 1. Study flowchart.
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While the trial was still ongoing, four similar phase 2 studies on
patients with MGMT-methylated refractory mCRC were pub-
lished, with conflicting results (Hochhauser et al,
2013; Pietrantonio et al, 2014, 2016; Amatu et al, 2016).
Hochhauser et al (2013) reported a disappointing RR of 3%
among 31 patients treated with a 7-day-on/7-day-off schedule for
each 28-day cycle. Similarly, Amatu et al (2016) failed to
demonstrate a meaningful activity of TMZ, reporting a PFS rate
at 12 weeks of 10.3% for 29 patients treated with a standard
schedule of TMZ (200 mg m 2 on days 1–5 of 28-day cycles). In
contrast, Pietrantonio et al (2014, 2016) observed a promising
activity of TMZ in this setting, reporting a RR of 12% among 32
patients receiving the standard schedule (150 mg m 2 on days 1–5
of 28-day cycles) and of 16% among 32 patients treated with a
dose-dense schedule (75 mg m 2 on days 1–21 of 28-day cycles).
Interestingly, the observed RR in the present study (10%) and
median survival times (median PFS and OS of 1.9 and 5.1 months,
respectively) are consistent with those reported by Pietrantonio
et al (2014, 2016), and somewhat comparable to those achieved by
regorafenib (Grothey et al, 2013) or TAS-102 (Mayer et al, 2015) in
randomised phase 3 trials. Furthermore, in our study TMZ was
well tolerated with an acceptable toxicity profile, consisting mostly
of grade 1 or 2 AEs (84%).
Taken together, these data suggest that TMZ has activity against
MGMT-methylated mCRC, but probably further investigation of
other possible predictive biomarkers may contribute to select truly
responsive patients leading to better results. A proposed biomarker
is the mutational status of RAS/BRAF genes. In fact, in their study
with standard schedule of TMZ, Pietrantonio et al (2014) observed
objective responses only in RAS/BRAF WT patients. It was
therefore postulated that RAS mutations could enhance MGMT
transduction through hyperactivation of the MAPK pathway,
leading to a MGMT-mediated resistance to TMZ. On the contrary,
when TMZ was given with a dose-dense schedule (Pietrantonio
et al, 2016), the authors observed responses exclusively in RAS- or
BRAF-mutated patients, speculating that a dose-dense schedule
could enhance sensitivity to TMZ in RAS-mutated mCRC as a
result of MGMT depletion due to cumulative dose and protracted
drug exposure. In our study, we did not observe a significant
difference in terms of TMZ activity among RAS MT and WT
patients. Moreover, all patients who experienced an objective
response had RAS MT tumours (three KRAS and one NRAS). This
observation is in contrast with the hypothesis that RAS mutations
are responsible for resistance to TMZ. Therefore, data on the role
of RAS/BRAF mutational status as a biomarker of TMZ activity, as
well as data on a possible correlation of the schedule with TMZ
activity according to RAS/BRAF mutational status, are not conclusive.
Another suggested biomarker is the MMR pathway status, on whose
integrity could rely the mechanism of cell death induced by TMZ
(Inno et al, 2014). The study by Hochhauser et al (2013) suggested
that a proficient MMR seems to be required to achieve the
therapeutic effects of TMZ. Indeed, all patients achieving a PR as
best response were MMR-proficient and most patients with an SD or
PD were MMR-deficient. However, given the low number of PR no
inference could be drawn by the authors. Moreover, the absence of
MMR-deficient tumours in the studies by Pietrantonio et al (2014,
2016) and the low frequency in our cohort do not allow to identify a
correlation between MMR status and response to TMZ.
Preclinical models suggest other possible mechanisms of
resistance to TMZ, including the base excision repair enzyme
alkylpurine-DNA N-glycosylase involved in repairing N3-methy-
ladenine and N7-methylguanine (Agnihotri et al, 2012), but its role
in the clinical setting is not yet defined.
A possible limitation of our study is represented by the
assessment of MGMT methylation on archival biopsies. Amatu
et al (2016) reported a significant decline in MGMT methylation
from archival samples compared with tumour or liquid biopsies
taken at the time of therapy start. In our study, the median time
Table 1. Patient’s and tumour’s characteristics
No. %
Patients 41









Right colon 7 17.5
Left colon 27 67.5
Rectum 6 15



























Abbreviations: ECOG¼Eastern Cooperative Oncology Group; MMR¼mismatch repair
system; PS, performance status.
Table 2. Efficacy results according to RECIST 1.1











Abbreviations: CI¼ confidence interval; CR¼ complete response; DCR¼disease control
rate; DoR¼duration of response; ORR¼overall response rate; OS¼overall survival;
PFS¼progression-free survival; PD¼progressive disease; PR¼partial response;
RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼ stable disease.
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from histological diagnosis on primary tumour or metastases and
the start of TMZ treatment was 3 years (range 1–7, 4 years). Thus,
given the dynamic epigenetic nature of this biomarker, during the
long interval between tumour biopsy and start of TMZ and under
the selective pressure of previous lines of therapy, MGMT
methylation might have been lost in an unpredictable percentage
of patients, leading to a lower than expected RR in our study. On
the other hand, a long-term storage of paraffin-embedded samples
could cause a reduction in MGMT methylation status, lowering the
sensitivity of MS-PCR (Kalmár et al, 2015).
Another limit might be related to the assay used to perform
molecular selection of patients in this setting. Sartore-Bianchi et al
(2017) recently conducted a pooled retrospective analysis on MS-
PCR (MSP)-positive tumour samples from 105 patients treated
within four phase 2 studies on alkylating agents (TMZ or
dacarbazine) (Amatu et al, 2013, 2016; Pietrantonio et al, 2014,
2016). This analysis assessed MGMT expression by IHC and digital
PCR methylation assay (methyl-BEAMing, MB) and evaluated the
association with clinical outcome, identifying a subgroup of
patients with a combined IHC low score/MB high level displaying
a significant reduction in the hazards of progression and death.
The authors showed that selection for MGMT deficiency by MSP
might not be sufficient to achieve the best efficacy of alkylating
treatment, whereas a combination of IHC and MB testing could



















































































































































1.9 months (95% CI 1.6–2.35)
5.1 months (95% CI 3.9–6.2)
Progression free survival Overall survival
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Figure 3. (A) Kaplan–Meier curve for PFS in the ITT population and (B) Kaplan–Meier curve for OS in the ITT population.
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enhance patient selection in this setting. Based on these results,
future prospective trials could require an optimised molecular
selection with combined techniques.
In conclusion, in the present study, TMZ achieved an RR of 10%
in heavily pretreated patients with MGMT-methylated mCRC, not
reaching the prespecified threshold of activity. However, taking
into account the evidence from other similar studies and also the
possible unreliability of the assessment of MGMT methylation in
archival samples, a role of TMZ in mCRC cannot be definitively
excluded. Future research should elucidate the appropriate timing
of MGMT methylation assessment as well as the mechanisms of
primary resistance to TMZ, to enhance TMZ activity by identifying
responsive patients. Therefore, when planning future trials with
TMZ in mCRC, a liquid or tissue biopsy at the moment of starting
therapy and a wide panel of potential biomarkers should be
considered. Moreover, as MGMT methylation is an early event of
CRC tumourigenesis that could be lost over time, the activity of
TMZ may be higher in earlier lines of treatment than in subsequent
lines. In this regard, a randomised phase 2 trial comparing 1 : 1
TMZ plus capecitabine (CAPTEM) vs FOLFIRI in patients with
MGMT-methylated, RAS-mutated mCRC after failure of prior
first-line oxaliplatin-based treatment is currently ongoing
(Berenato et al, 2016).
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